缺血性脑卒中患者再通治疗后的二级预防

European Pharmaceutical Journal Pub Date : 2022-07-01 DOI:10.2478/afpuc-2022-0013

Michaela Benešová, M. Krivošík, S. Kosirova, T. Foltanova

{"title":"缺血性脑卒中患者再通治疗后的二级预防","authors":"Michaela Benešová, M. Krivošík, S. Kosirova, T. Foltanova","doi":"10.2478/afpuc-2022-0013","DOIUrl":null,"url":null,"abstract":"Abstract We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.","PeriodicalId":12070,"journal":{"name":"European Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Secondary prevention of patients with ischaemic stroke after recanalization treatment\",\"authors\":\"Michaela Benešová, M. Krivošík, S. Kosirova, T. Foltanova\",\"doi\":\"10.2478/afpuc-2022-0013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.\",\"PeriodicalId\":12070,\"journal\":{\"name\":\"European Pharmaceutical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Pharmaceutical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/afpuc-2022-0013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/afpuc-2022-0013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

摘要我们对100例缺血性脑卒中患者进行了回顾性分析。所有患者在急性护理环境中接受静脉溶栓治疗（平均2.8小时，最大4.5小时），其中10人还接受了机械血栓切除术。对于20%的患者来说，中风是致命的。门到针的时间为38.46分钟。尽管抗血栓治疗的变化是由于中风引起的，但在接受抗血栓治疗和未接受抗血栓药物治疗的患者之间，国家卫生研究所中风量表评分没有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Secondary prevention of patients with ischaemic stroke after recanalization treatment

Abstract We performed a retrospective analysis of 100 patients with ischaemic stroke. All patients underwent intravenous thrombolysis in the acute care setting (avg. 2.8 hours, max 4.5 hours) and 10 of them also underwent mechanical thrombectomy. For 20% of the patients, the stroke was fatal. Door to needle time was 38.46 minutes. Although changes in antithrombotic treatment were introduced due to strokes, there was no significant difference in National Institute of Health Stroke Scale scores between the patients who were on antithrombotic treatment and those who were on no antithrombotic treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Pharmaceutical Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： European Pharmaceutical Journal publishes only original articles not previously published and articles that are not being considered or have not been submitted for publication elsewhere. If parts of the results have been published as conference abstract or elsewhere, it should be stated in references. The ethical standards of the Helsinki-Tokio Declaration should be kept. This should be mentioned in the Methods of manuscript. Reviews are published only on request. Authors, whose submitted research work was performed with the support of a company, should indicate this in Conflict of Interest.